Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

UK cost agency endorses Novartis heart drug for some patients

Novartis’s big new drug hope Entresto has been recommended for use in some patients with heart failure by Britain’s cost agency NICE, which said on Friday it believed the treatment was a cost-effective option.   Entresto has a list price of 1,194 pounds ($1,809) a year in Britain, or less than half the price of […]

Read More »

Sales and Marketing: IMS projects narrowing use gap, slowing med spend growth over next five years

More than half of the world’s population will live in countries where medicine use will exceed one dose per person per day by 2020, up from 31 percent in 2005, as the “medicine use gap” between developed and pharmerging markets narrows, according to research by the IMS Institute for Healthcare Informatics.

Read More »

Senate panel focuses on toll of Valeant, Turing drug price spikes

A pediatric doctor in Alabama had to scramble to find a less expensive supply of a lifesaving drug to treat an infant who was suffering from a parasitic infection.   In Utah, a hospital has been forced to change the way it stocks a drug critical to treating heart patients after the cost skyrocketed from […]

Read More »

Trial for Bayer’s Xarelto under scrutiny over defective device

European and U.S. drug regulators are looking into whether a defective blood clotting test device affected a trial involving Bayer’s top-selling anti-clotting drug Xarelto, hitting the German drugmaker’s shares. The study compared Xarelto, also known as rivaroxaban, with older drug warfarin for preventing strokes in patients with a type of irregular heartbeat common among the […]

Read More »

Teva gets FDA approval for cancer drug

Israel’s Teva Pharmaceutical Industries said the U.S. Food and Drug Administration approved an injectable and infusion version of its cancer drug bendamustine. The drug, sold under the brand name Bendeka, is approved for treating cancer patients with chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma. Teva, which has licensed the drug from Eagle Pharmaceuticals Inc, […]

Read More »

Tonix Pharma, U.S. Defense Department partner on PTSD drug

Tonix Pharmaceuticals Holding Corp said it was teaming up with the U.S. Department of Defense to further develop its experimental PTSD drug, which if approved, could be the first treatment for the psychiatric disorder in more than 15 years. The Cooperative Research and Development Agreement with the Department of Defense will allow Tonix to gain […]

Read More »

Amgen And Merck Announce Cancer Immunotherapy Collaboration For Patients With Non-Hodgkin Lymphoma

THOUSAND OAKS, Calif. and KENILWORTH, N.J., Dec. 4, 2015 /PRNewswire/ — Amgen (NASDAQ: AMGN) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced a cancer immunotherapy collaboration to support a Phase 1b/3 study investigating BLINCYTO® (blinatumomab) in combination with KEYTRUDA® (pembrolizumab) in patients with diffuse large B-cell lymphoma (DLBCL), which […]

Read More »

Turing’s Martin Shkreli Says He Should Have Increased the Price of Daraprim Higher than 5,000%

NEW YORK – Turing Pharmaceuticals’ Martin Shkreli, once dubbed the most hated man in America, might not have a difficult time holding onto that title after telling a healthcare panel he should have raised the price of Daraprim even higher than the 5,000 percent increase he did. “I think I could have raised it higher […]

Read More »

INSYS Responds to Allegations It Falsified Reports to Sell More of its Cancer Pain Treatment

PHOENIX – After its stock dropped nearly 20 percent, Insys Therapeutics defended its practices from allegations it falsified data in order to sell more of its painkiller, the fentanyl-based Subsys. The Arizona-based company said it is committed to patient safety and has complied with all law, including those related to adverse event reporting.   In […]

Read More »

Researchers Find Additional Benefits of Novartis AG’s Heart Failure Drug Entresto

Researchers at Brigham and Women’s Hospital have discovered even more promising data around a Novartis drug for heart failure, saying that the drug increased life expectancy by nearly two years. The research, published in the Dec. 3 issue of the New England Journal of Medicine, showed that patients that had reduced ejection fraction form — […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom